Home LiteratureArticle Details
PMID: 16189008 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.

Journal of virology ·Vol. 79 ·No. 20 ·2005-10-00 ·Pages 13060-9

Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM

Abstract

We have determined the crystal structure of the Fab fragment from F105, a broadly reactive human antibody with limited potency that recognizes the CD4 binding site of gp120. The structure reveals an extended CDR H3 loop with a phenylalanine residue at the apex and shows a striking pattern of serine and tyrosine residues. Modeling the interaction between gp120 and F105 suggests that the phenylalanine may recognize the binding pocket of gp120 used by Phe(43) of CD4 and that numerous tyrosine and serine residues form hydrogen bonds with the main chain atoms of gp120. A comparison of the F105 structure to that of immunoglobulin G1 b12, a much more potent and broadly neutralizing antibody with an overlapping epitope, suggests similarities that contribute to the broad recognition of human immunodeficiency virus by both antibodies. While the putative epitope for F105 shows significant overlap with that predicted for b12, it appears to differ from the b12 epitope in extending across the interface between the inner and outer domains of gp120. In contrast, the CDR loops of b12 appear to interact predominantly with the outer domain of gp120. The difference between the predicted epitopes for b12 and F105 suggests that the unique potency of b12 may arise from its ability to avoid the interface between the inner and outer domains of gp120.

MeSH Terms
Amino Acid Sequence Antibody Specificity CD4 Antigens/immunology,metabolism Complementarity Determining Regions/chemistry Crystallography HIV Antibodies/chemistry,immunology HIV Envelope Protein gp120/immunology,metabolism HIV-1/immunology Immunoglobulin Fab Fragments/chemistry,immunology Models, Molecular Molecular Sequence Data
Chemicals
CD4 Antigens Complementarity Determining Regions HIV Antibodies HIV Envelope Protein gp120 Immunoglobulin Fab Fragments
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Wilkinson Royce A
Department of Chemistry and Biochemistry, Montana State University, Bozeman, 59717, USA.
Piscitelli Chayne
Teintze Martin
Cavacini Lisa A
Posner Marshall R
Lawrence C Martin
References (71)
71 references, click to expand
  1. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Biochemistry. 1999 Jul 20;38(29):9405-16 PMID: 10413516
  2. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  3. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Nat Med. 2000 Feb;6(2):200-6 PMID: 10655110
  4. Energetics of the HIV gp120-CD4 binding reaction.
    Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9026-31 PMID: 10922058
  5. Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1.
    Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):168-71 PMID: 11134947
  6. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
    Structure. 2000 Dec 15;8(12):1329-39 PMID: 11188697
  7. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Science. 2001 Aug 10;293(5532):1155-9 PMID: 11498595
  8. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
    Vaccine. 2002 May 6;20(15):1956-60 PMID: 11983253
  9. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 2002 Oct;76(19):9888-99 PMID: 12208966
  10. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
    J Virol. 2003 Jan;77(1):642-58 PMID: 12477867
  11. CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.
    J Virol. 2003 Jan;77(1):713-8 PMID: 12477875
  12. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  13. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen.
    J Mol Biol. 2003 Jan 10;325(2):337-54 PMID: 12488099
  14. QSYP peptide sequence is selected from phage display libraries by bovine IgG contaminants in monoclonal antibody preparations.
    Biotechniques. 2003 Jan;34(1):132-4, 137-41 PMID: 12545550
  15. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  16. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
    J Virol. 2003 May;77(10):5863-76 PMID: 12719580
  17. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    J Virol. 2003 Jun;77(12):6965-78 PMID: 12768015
  18. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.
    Cell. 2003 Jul 25;114(2):161-70 PMID: 12887918
  19. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 1992 Sep;66(9):5635-41 PMID: 1380099
  20. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures.
    J Mol Biol. 2003 Dec 5;334(4):733-49 PMID: 14636599
  21. Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design.
    Adv Exp Med Biol. 2003;535:55-66 PMID: 14714888
  22. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
    Biochemistry. 2004 Feb 17;43(6):1410-7 PMID: 14769016
  23. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.
    Structure. 2004 Feb;12(2):193-204 PMID: 14962380
  24. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.
    Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2706-11 PMID: 14981267
  25. HIV vaccine design and the neutralizing antibody problem.
    Nat Immunol. 2004 Mar;5(3):233-6 PMID: 14985706
  26. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    J Virol. 2004 Mar;78(6):3155-61 PMID: 14990736
  27. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.
    Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12467-72 PMID: 15306681
  28. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.
    AIDS Res Hum Retroviruses. 2004 Jul;20(7):755-62 PMID: 15307922
  29. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
    Protein Eng Des Sel. 2004 Oct;17(10):749-58 PMID: 15542540
  30. Structure of an unliganded simian immunodeficiency virus gp120 core.
    Nature. 2005 Feb 24;433(7028):834-41 PMID: 15729334
  31. On the nature of antibody combining sites: unusual structural features that may confer on these sites an enhanced capacity for binding ligands.
    Proteins. 1990;7(2):112-24 PMID: 1691497
  32. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
  33. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
    J Immunol. 1991 Jun 15;146(12):4325-32 PMID: 1710248
  34. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    J Exp Med. 1991 Aug 1;174(2):407-15 PMID: 1713252
  35. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
    J Virol. 1991 Nov;65(11):6188-93 PMID: 1717717
  36. [Model phases: probabilities and bias.
    Methods Enzymol. 1997;277:110-28 PMID: 18488308
  37. Structure, function and properties of antibody binding sites.
    J Mol Biol. 1991 Jan 5;217(1):133-51 PMID: 1988675
  38. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.
    Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189-93 PMID: 2006155
  39. Improved methods for building protein models in electron density maps and the location of errors in these models.
    Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9 PMID: 2025413
  40. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  41. [20] Processing of X-ray diffraction data collected in oscillation mode.
    Methods Enzymol. 1997;276:307-326 PMID: 27799103
  42. Measurement of protein using bicinchoninic acid.
    Anal Biochem. 1985 Oct;150(1):76-85 PMID: 3843705
  43. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites.
    J Biol Chem. 1977 Oct 10;252(19):6609-16 PMID: 408353
  44. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    J Virol. 1994 Dec;68(12):8350-64 PMID: 7525988
  45. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    J Immunol. 1995 Jan 15;154(2):893-906 PMID: 7529290
  46. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  47. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  48. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    J Virol. 1995 Jul;69(7):4413-22 PMID: 7769703
  49. Analysis of antigenic surfaces of proteins.
    FASEB J. 1995 Jan;9(1):87-93 PMID: 7821764
  50. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65.
    Proteins. 1994 Jan;18(1):49-62 PMID: 7908437
  51. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Mol Immunol. 1994 Oct;31(15):1149-60 PMID: 7935503
  52. Anatomy of the antibody molecule.
    Mol Immunol. 1994 Feb;31(3):169-217 PMID: 8114766
  53. Variable region genes of anti-HIV human monoclonal antibodies: non-restricted use of the V gene repertoire and extensive somatic mutation.
    Mol Immunol. 1993 Nov;30(16):1543-51 PMID: 8232339
  54. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
  55. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
    J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14 PMID: 8417177
  56. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  57. Interactions of protein antigens with antibodies.
    Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):7-12 PMID: 8552677
  58. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.
    J Virol. 1996 Sep;70(9):6437-41 PMID: 8709277
  59. Accessing the Kabat antibody sequence database by computer.
    Proteins. 1996 May;25(1):130-3 PMID: 8727325
  60. Antibody-antigen interactions: contact analysis and binding site topography.
    J Mol Biol. 1996 Oct 11;262(5):732-45 PMID: 8876650
  61. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  62. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    J Infect Dis. 1997 May;175(5):1056-62 PMID: 9129066
  63. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  64. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
    J Virol. 1998 Apr;72(4):3235-40 PMID: 9525650
  65. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
    J Virol. 1998 May;72(5):3512-9 PMID: 9557629
  66. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  67. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  68. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  69. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
    AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80 PMID: 9764911
  70. The atomic structure of protein-protein recognition sites.
    J Mol Biol. 1999 Feb 5;285(5):2177-98 PMID: 9925793
  71. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).
    J Biol Chem. 1999 Feb 12;274(7):4115-23 PMID: 9933605
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-10-00
Pages
13060-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1235812
Subset
IM
Grants
NIAID NIH HHS · R01 AI026926 · United States
NIAID NIH HHS · R21 AI049753 · United States
NIAID NIH HHS · AI26926 · United States
NIAID NIH HHS · AI49753 · United States
Databases
PDB
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com